Darzalex 100mg Injection

About

Daratumumab, marketed as Darzalex, is a human CD38-directed monoclonal antibody indicated for the treatment of multiple myeloma. CD38 is a transmembrane glycoprotein that is highly expressed on the surface of multiple myeloma cells, as well as on other hematopoietic and lymphoid cells. Daratumumab binds to CD38 on myeloma cells and induces cell death through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis.

This targeted therapy also modulates the activity of certain immune suppressor cells, such as regulatory T cells, myeloid-derived suppressor cells, and B cells, which also express CD38. By depleting these cells, Daratumumab may enhance anti-tumor immune responses. It is often used in combination with other agents like lenalidomide, bortezomib, and dexamethasone, or as a monotherapy in patients who have received prior therapies. Its introduction has significantly improved outcomes for patients with relapsed or refractory multiple myeloma, offering a novel approach to disease management.

Uses

• Treatment of newly diagnosed multiple myeloma in combination with other agents.
• Treatment of relapsed or refractory multiple myeloma in combination with other agents.
• Monotherapy for multiple myeloma patients who have received at least three prior lines of therapy.
• Treatment of multiple myeloma in patients ineligible for autologous stem cell transplant.

Directions For Use

Darzalex 100mg Injection is administered intravenously by a healthcare professional. The dosage and infusion schedule are determined by your doctor.

Benefits

• Effective in treating multiple myeloma.
• Induces cell death through multiple immune mechanisms.
• Can be used as monotherapy or in combination.
• Improves progression-free survival in multiple myeloma.
• Offers a targeted approach to cancer therapy.
• Provides a crucial option for relapsed/refractory patients.

Side Effects

• Infusion-related reactions (chills, shortness of breath, cough)
• Fatigue
• Nausea
• Diarrhea
• Upper respiratory tract infection
• Cough
• Pyrexia
• Peripheral edema
• Back pain
• Anemia
• Thrombocytopenia
• Neutropenia

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol use may worsen fatigue or gastrointestinal side effects.
• Pregnancy - Daratumumab is not recommended during pregnancy due to potential fetal harm. Use effective contraception during and for at least 3 months after treatment.
• Breastfeeding - It is unknown if Daratumumab is excreted in human milk. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for 3 months after.
• Liver - No specific dose adjustment is typically required for hepatic impairment, but use with caution and monitor liver function.
• Kidney - No specific dose adjustment is typically required for renal impairment, but use with caution and monitor kidney function.
• Lung - Monitor for respiratory symptoms, especially during infusions, due to potential for infusion-related reactions and lung complications.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.